^
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive
:
A1
No biomarker
Cutaneous Melanoma
TC
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
trametinib
Resistant
:
A2
BRAF V600
Cutaneous Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
paclitaxel
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
temozolomide
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
dacarbazine
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
pembrolizumab + ipilimumab
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
dabrafenib + SNR1611
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive
:
A2
BRAF V600K
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600K
Cutaneous Melanoma
pembrolizumab
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
pembrolizumab
Sensitive
:
A2
BRAF V600K
Cutaneous Melanoma
nivolumab
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
nivolumab
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
nivolumab
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
pembrolizumab
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive
:
A2
No biomarker
Cutaneous Melanoma
talimogene laherparepvec
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our